Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 15, 2022
Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic coughPeter V Dicpinigaitis, Surinder S Birring, Michael Blaiss, et al.Lung|July 27, 2022
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined SubgroupsJaclyn A Smith, Surinder S Birring, Peter V Dicpinigaitis, et al.Lancet (London, England)|March 6, 2022
Efficacy and safety of gefapixant, a P2X<sub>3</sub> receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trialsLorcan P McGarvey, Surinder S Birring, Alyn H Morice, et al.Journal of the National Cancer Institute|June 24, 2024
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 studyRebecca Dent, Javier Cortés, Lajos Pusztai, et al.Journal of the National Cancer Institute|December 9, 2023
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355David W Cescon, Peter Schmid, Hope S Rugo, et al.The Lancet. Oncology|March 6, 2023
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trialBradley J Monk, Krishnansu S Tewari, Coraline Dubot, et al.European Journal of Cancer (Oxford, England : 1990)|April 22, 2023
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's ChoiceDomenica Lorusso, Nicoletta Colombo, Antonio Casado Herraez, et al.European Journal of Cancer (Oxford, England : 1990)|November 17, 2023
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 studyPeter Schmid, Oleg Lipatov, Seock-Ah Im, et al.European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.Gynecologic Oncology|July 1, 2025
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancerLeslie Randall, Yang Xiang, Takashi Matsumoto, et al.Pageof 4